171P Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer

Authors :: F. Marmé
H. Wildiers
L. Dirix
A. Armstrong
E. De Cuypere
F. Dalenc
C. Pia Schröder
P. Vuylsteke
E. Brain
S. Kuemmel
Z. Pápai
C. Mueller
C. Brignone
F. Triebel
Source :: Annals of Oncology. 33:S203-S204
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools